Concept Life Sciences, a leading contract research organisation (CRO) specialising in drug discovery and development, materials science, and safety toxicology, has appointed Dean Bornilla as Chief Commercial Officer (CCO) to spearhead its international growth strategy, with a focus on expanding its presence in North America and Europe.
The appointment brings more than 25 years of life sciences commercial leadership experience to Concept as the company looks to strengthen its position in key global markets, deepen strategic customer relationships and broaden access to its specialist scientific capabilities.
Bornilla joins the company following senior commercial leadership roles at Pace Life Sciences, Selvita and Curia (formerly AMRI), where he led commercial growth initiatives, international market expansion and strategic customer development across the CRO, CDMO and pharmaceutical sectors.
As Chief Commercial Officer, Bornilla will lead the company’s global commercial operations, including sales, business development, marketing and strategic account management. A key priority will be connecting pharmaceutical, biotechnology and wider scientific organisations with Concept’s integrated scientific services, helping customers address increasingly complex research and development challenges.
Dr. Adrijana Vinter, Chief Executive Officer of Concept Life Sciences, commented: “Dean Bornilla joins us at an important stage in our growth strategy. With considerable experience across the scientific services sector, he brings the commercial expertise, international perspective and customer focus needed to help us realise our ambitions.
“Our scientific capabilities provide a strong foundation for growth, and this appointment is about building on that strength. He will play a key role in expanding our reach in priority markets, developing deeper customer partnerships and ensuring more organisations can benefit from the breadth of expertise we offer.”
Dean Bornilla, Chief Commercial Officer of Concept Life Sciences, commented:
“Concept Life Sciences has an impressive breadth of scientific expertise and a strong reputation for helping customers solve complex challenges. What attracted me to the business is the opportunity to build on those strengths and bring its capabilities to a wider international customer base. Our differentiated capabilities across drug discovery and development, material sciences, and safety toxicology position us to address a broad range of increasingly complex scientific challenges.
“My priority will be to strengthen our commercial organisation, deepen relationships with existing customers and open new opportunities in North America, Europe and other strategic markets. By connecting customers with the right expertise across our portfolio, we can support their innovation goals while delivering sustainable growth for the business.”
